Disc Medicine (IRON) Capital Expenditures (2021 - 2025)
Disc Medicine (IRON) reported Capital Expenditures of $20000.0 for Q4 2025, down 95.55% year-over-year from $449000.0 in Q4 2024, and down 23.08% on a QoQ basis from $26000.0 in Q3 2025.
Disc Medicine (IRON) has 5 years of Capital Expenditures data on file, last reported at $20000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 95.55% year-over-year to $20000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $82000.0 (down 93.64% YoY) and the FY2025 annual result came in at $933000.0, up 84.75% from the prior year.
- Capital Expenditures slipped to $20000.0 in Q4 2025 per IRON's latest filing, from $26000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $851000.0 in Q1 2025 and bottomed at -$51000.0 in Q4 2021.
- The 5-year median for Capital Expenditures is $20000.0 (2022), against an average of $95705.9.
- Peak annual rise in Capital Expenditures reached 14866.67% in 2024, while the deepest fall reached 125.0% in 2024.
- Tracing IRON's Capital Expenditures over 5 years: stood at -$51000.0 in 2021, then jumped by 123.53% to $12000.0 in 2022, then tumbled by 75.0% to $3000.0 in 2023, then jumped by 14866.67% to $449000.0 in 2024, then tumbled by 95.55% to $20000.0 in 2025.
- Per Business Quant, the three latest IRON Capital Expenditures figures stand at $20000.0 (Q4 2025), $26000.0 (Q3 2025), and $36000.0 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | Disc Medicine | 2.76 Bn | 2.03 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 20,000.00 |
| Dec 31, 2025 | 20,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Sep 30, 2025 | 26,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Jun 30, 2025 | 36,000.00 |
| Mar 31, 2025 | 851,000.00 |
| Mar 31, 2025 | 851,000.00 |
| Dec 31, 2024 | 449,000.00 |
| Dec 31, 2024 | 449,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Sep 30, 2024 | -8,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Jun 30, 2024 | -3,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Mar 31, 2024 | 67,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Sep 30, 2023 | 45,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Jun 30, 2023 | 12,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Mar 31, 2023 | 29,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Dec 31, 2022 | 12,000.00 |
| Sep 30, 2022 | 19,000.00 |
| Sep 30, 2022 | 19,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Jun 30, 2022 | 20,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | -51,000.00 |
| Dec 31, 2021 | -51,000.00 |